Alto Neuroscience Inc. (ANRO) is a publicly traded Healthcare sector company. As of May 21, 2026, ANRO trades at $20.78 with a market cap of $765.05M and a P/E ratio of -8.22. ANRO moved +1.71% today. Year to date, ANRO is +25.71%; over the trailing twelve months it is +614.09%. Its 52-week range spans $1.60 to $28.44. Analyst consensus is strong buy with an average price target of $35.22. Rallies surfaces ANRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Alto Neuroscience Initiates Phase 2b Trial, Secures $120M PIPE, $264M Cash: Alto Neuroscience initiated its pivotal Phase 2b trial of ALTO-207 in treatment-resistant depression in April, enrolling 178 adults with two to five prior treatment failures. The company closed a $120 million PIPE in March and ended Q1 with $264 million cash, funding operations through 2029.
| Metric | Value |
|---|---|
| Price | $20.78 |
| Market Cap | $765.05M |
| P/E Ratio | -8.22 |
| EPS | $-2.50 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.44 |
| 52-Week Low | $1.60 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-61.43M |
| Gross Margin | 0.00% |
11 analysts cover ANRO: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.22.